文献速递免疫规划传染病防控与疫情报告

COVID-19疫苗接种后的听前庭不良事件

Audiovestibular adverse events following COVID-19 vaccinations.
PubMed 文献 · Vaccine · 2024-02-22

本研究应用多数据源方法,对2021年1月至2023年3月澳大利亚东南部COVID-19疫苗接种后的听前庭事件进行分析,包括对SAEFVIC自发报告进行回顾性观察分析,以及利用POLAR工具收集的全科医学数据开展自对照病例系列分析。结果显示,mRNA疫苗接种后眩晕的全科就诊表现增加(RI=1.40,P<.001),Vaxzevria®腺病毒载体疫苗和mRNA疫苗接种后耳鸣增加(RI分别为2.25,P<.001和1.53,P<.001),任何COVID-19疫苗接种后听力损失均未增加。

要点

  • mRNA疫苗接种后眩晕的全科就诊表现增加(RI=1.40,P<.001)。
  • Vaxzevria®腺病毒载体疫苗和mRNA疫苗接种后耳鸣增加(RI=2.25,P<.001和1.53,P<.001)。
  • 任何COVID-19疫苗接种后听力损失均未增加。

核心结论

  • 本研究首次证明mRNA疫苗接种后眩晕的全科就诊表现增加,以及Vaxzevria®腺病毒载体疫苗和mRNA疫苗接种后耳鸣增加。
  • 任何COVID-19疫苗接种后听力损失均未增加。
  • 医疗服务提供者和受种者应警惕COVID-19疫苗接种后潜在的听前庭主诉。
  • 本研究强调使用大型真实世界数据集为公共卫生决策收集可靠证据的重要性。

研究设计与样本

  • 本研究应用多数据源方法,包括对SAEFVIC的自发听前庭事件报告进行回顾性观察分析,以及利用POLAR工具收集的全科医学数据开展自对照病例系列分析。
  • 研究地点为澳大利亚东南部,时间为2021年1月至2023年3月。

主要发现

  • mRNA疫苗接种后眩晕的全科就诊表现增加(RI=1.40,P<.001)。
  • Vaxzevria®腺病毒载体疫苗接种后耳鸣增加(RI=2.25,P<.001)。
  • mRNA疫苗接种后耳鸣增加(RI=1.53,P<.001)。
  • 任何COVID-19疫苗接种后听力损失均未增加。

临床怎么用

  • 医疗服务提供者和受种者应警惕COVID-19疫苗接种后潜在的听前庭主诉。
  • 本研究强调使用大型真实世界数据集为公共卫生决策收集可靠证据的重要性。

局限性

  • 本研究无法考虑同时发生COVID-19感染的潜在可能,文献表明其与听前庭事件相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Evidence regarding audiovestibular adverse events post COVID-19 vaccination to date has been inconclusive regarding a potential association. This study aimed to determine if there was an increase in audiovestibular events following COVID-19 vaccination in South-eastern Australia during January 2021-March 2023. METHODS: A multi-data source approach was applied. First, a retrospective observational analysis of spontaneous reports of audiovestibular events to a statewide vaccine safety surveillance service, SAEFVIC. Second, a self-controlled case series analysis using general practice data collected via the POpulation Level Analysis and Reporting (POLAR) tool. RESULTS AND CONCLUSIONS: This study is the first to demonstrate an increase in general practice presentations of vertigo following mRNA vaccines (RI = 1.40, P <.001), and tinnitus following both the Vaxzevria® adenovirus vector and mRNA vaccines (RI = 2.25, P <.001 and 1.53, P <.001 respectively). There was no increase in hearing loss following any COVID-19 vaccinations. Our study, however, was unable to account for the potential of concurrent COVID-19 infections, which literature has indicated to be associated with audiovestibular events. Healthcare providers and vaccinees should be alert to potential audiovestibular complaints after COVID-19 vaccination. Our analysis highlights the importance of using large real-world datasets to gather reliable evidence for public health decision making.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shetty AN, Morgan HJ, Phuong LK, et al. Audiovestibular adverse events following COVID-19 vaccinations. Vaccine. 2024. PMID: 38395721. doi:10.1016/j.vaccine.2024.02.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。